Chronic Hepatitis B Virus Market

DelveInsight's "Chronic Hepatitis B (CHB) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the chronic hepatitis B, historical and forecasted epidemiology as well as the chronic hepatitis B market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Chronic Hepatitis B (CHB) market report provides current treatment practices, emerging drugs, chronic hepatitis B market share of the individual therapies, current and forecasted chronic hepatitis B market size from 2019 to 2032 segmented by seven major markets. The report also covers current chronic hepatitis B treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Chronic Hepatitis B (CHB) Understanding and Treatment Algorithm

The DelveInsight’s Chronic Hepatitis B (CHB) epidemiology report gives a thorough understanding of chronic hepatitis B by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Chronic Hepatitis B (CHB) has been described as “a heterogeneous disease with markedly variable levels of viral replication and liver disease activity”. It is characterized by liver injury mediated by a T-cell immune response targeting hepatocytes that express viral antigens. It can lead to the development of chronic hepatitis, cirrhosis, and HCC. As well as in HCV, chronic HBV infection is associated with age, cell cycle arrest, and CS.

 

Chronic hepatitis B is usually asymptomatic. The most common symptom is fatigue, but sleep disorders, difficulty concentrating, and upper right quadrant pain are often observed. Chronic hepatitis B infection lasts six months or longer. It lingers because the immune system can't fight off the infection. Chronic hepatitis B infection may last a lifetime, possibly leading to serious illnesses such as cirrhosis and liver cancer. The risk of developing a chronic hepatitis B infection is also directly related to the age at which one first becomes exposed to the hepatitis B virus. 

 

Diagnosis

Chronic infection may go undetected for decades until a person becomes seriously ill from liver disease. If signs of liver damage are present, the doctor will perform several tests to diagnose chronic hepatitis B, including blood tests to detect signs of hepatitis B virus in the body and liver ultrasound and biopsy to determine the amount of liver damage. Doctors sometimes also test certain healthy people for hepatitis B infection because the virus can damage the liver before causing signs and symptoms.

Chronic Hepatitis B (CHB) Epidemiology 

The epidemiology section provides insights into the historical and current chronic hepatitis B patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
 
 

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted chronic hepatitis B epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

In the year 2021, the total diagnosed prevalent cases of chronic hepatitis B were 2,165,851 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted chronic hepatitis B epidemiology [segmented as Prevalent population Cases of CHB, Diagnosed prevalent cases of CHB, Gender-specific cases of CHB, Age-Specific cases of CHB, Type-specific cases of CHB, and Total Treated Cases of CHB] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Chronic Hepatitis B (CHB) Epidemiology

The epidemiology segment also provides the chronic hepatitis B epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chronic Hepatitis B (CHB) Drug Chapters

The drug chapter segment of the Chronic Hepatitis B (CHB) report encloses the detailed analysis of chronic hepatitis B marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the chronic hepatitis B clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for chronic hepatitis B treatment.

Chronic Hepatitis B (CHB) Market Outlook

The chronic hepatitis B market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted chronic hepatitis B market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, barriers, and demand of better technology.

 

This segment gives a thorough detail of chronic hepatitis B market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Chronic Hepatitis B (CHB) market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

The Chronic Hepatitis B (CHB) market size in the 7MM is expected to change during the study period 2019–2032. The therapeutic market of chronic hepatitis B in the seven major markets is expected to increase during the study period (2019–2032). In 2021, the total market size of chronic hepatitis B was USD 2,605 million which is expected to rise during the study period (2019–2032).

 

The United States Market Outlook

The total market size of chronic hepatitis B in the United States accounted for USD 1,741 million in 2021 which is expected to rise during the study period (2019–2032).

 

EU-5 Countries: Market Outlook

In EU5, the total market size of chronic hepatitis B was USD 483 million in 2021, which is expected to rise during the study period (2019–2032).

 

Japan Market Outlook

In Japan, the total market size of chronic hepatitis B was USD 380 million in 2021, which is expected to rise during the study period (2019–2032).

Chronic Hepatitis B (CHB) Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Hepatitis B market or expected to get launched in the market during the study period 2019-2032. The analysis covers chronic hepatitis B market uptake by drugs; patient uptake by therapies; and sales of each drug.  

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Hepatitis B (CHB) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses chronic hepatitis B’s key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for chronic hepatitis B emerging therapies.

Reimbursement Scenario in Chronic Hepatitis B (CHB)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Chronic Hepatitis B domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or chronic hepatitis B market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Chronic Hepatitis B market by using various competitive intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of chronic hepatitis B, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight has been provided into the Chronic Hepatitis B epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for chronic hepatitis B are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Chronic Hepatitis B market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global chronic hepatitis B market

Report Highlights

  • In the coming years, the Chronic Hepatitis B market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence chronic hepatitis B R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
  • Major players are involved in developing therapies for chronic hepatitis B. The launch of emerging therapies will significantly impact the Chronic Hepatitis B market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for chronic hepatitis B
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Hepatitis B (CHB) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Hepatitis B (CHB) Pipeline Analysis
  • Chronic Hepatitis B (CHB) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Hepatitis B (CHB) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Chronic Hepatitis B (CHB) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chronic Hepatitis B (CHB) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Chronic Hepatitis B drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Chronic Hepatitis B total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings of the market across 7MM and which country will have the largest Chronic Hepatitis B market size during the forecast period (2019-2032)?
  • At what CAGR, the Chronic Hepatitis B market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Chronic Hepatitis B market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Chronic Hepatitis B market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of chronic hepatitis B?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical chronic hepatitis B patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of chronic hepatitis B in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about chronic hepatitis B?
  • Out of all 7MM countries, which country would have the highest prevalent population of chronic hepatitis B during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the chronic hepatitis B treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of chronic hepatitis B in the USA, Europe, and Japan?
  • What are the chronic hepatitis B marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of chronic hepatitis B?
  • How many therapies are in-development by each company for chronic hepatitis B treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for chronic hepatitis B treatment?
  • What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the chronic hepatitis B therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for chronic hepatitis B and its status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for chronic hepatitis B?
  • What are the global historical and forecasted markets of chronic hepatitis B?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Hepatitis B (CHB) market
  • To understand the future market competition in the Chronic Hepatitis B (CHB) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Hepatitis B (CHB) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Chronic Hepatitis B (CHB) market
  • To understand the future market competition in the Chronic Hepatitis B (CHB) market

1. Key Insights

2. Report Introduction

3. Chronic Hepatitis B Market Overview at a Glance

3.1. Market Share (%) Distribution of Chronic Hepatitis B in 2019

3.2. Market Share (%) Distribution of Chronic Hepatitis B in 2032

4. Executive Summary of Chronic Hepatitis B (CHB)

4.1. Key events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Acute and Chronic Hepatitis B Infection

6.3. Signs and Symptoms

6.4. Risk Factors and Causes

6.5. Transmission of Hepatitis B Virus

6.6. Pathophysiology

6.7. Stages of HBV Infection

6.8. Complications of Hepatitis B Virus Infection

7. Diagnosis of Hepatitis B Infection

7.1. Screening Tests for Hepatitis B Infection

7.2. Liver Related Blood Tests

7.3. Tests to Diagnose Hepatitis B Virus

7.3.1. Medical History and Physical exam

7.3.2. Imaging tests

7.3.3. MRI and CT Scans

7.4. Liver Biopsy for Hepatitis B Virus

7.5. Diagnostic Guidelines of Hepatitis B Infection

7.5.1. World Health Organization (WHO) Diagnostic Guidelines

7.5.2. American Association for the Study of Liver Diseases (AASLD) Diagnostic Guidelines

7.5.3. European Association for the Study of the Liver (EASL) Diagnostic Guidelines

7.6. Prevention of Hepatitis B Infection

8. Current Treatment Practices

8.1. Treatment Algorithm

8.2. Treatment Guidelines

8.2.1. AASLD 2018 Practice Guidelines for Treatment of Chronic Hepatitis

8.2.2. European Association for the Study of the Liver (EASL) 2017 Clinical Practice Guidelines for Hepatitis

8.2.3. Hepatitis B management: Guidance for the Primary Care Provider

8.2.4. World Health Organization Guidelines for the management and treatment of CHB

8.2.5. Japan Society of Hepatology for the Management of Hepatitis B Virus Infection (2014)

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Epidemiology of Chronic Hepatitis B

9.3. Epidemiology Scenario

9.3.1. Prevalent Population of Chronic Hepatitis B

9.3.2. Diagnosed Prevalent Cases of Chronic Hepatitis B

9.3.3. Gender-specific Cases of Chronic Hepatitis B

9.3.4. Age-specific Cases of Chronic Hepatitis B

9.3.5. Type-specific Cases of Chronic Hepatitis B

9.3.6. Total Treated Cases of Chronic Hepatitis B

10. Patient Journey of CHB

11. Key Endpoints in Chronic Hepatitis B Clinical Trials

12. Marketed Therapies

12.1. Vemlidy (tenofovir alafenamide): Gilead Sciences

12.1.1. Product Description

12.1.2. Regulatory Milestones

12.1.3. Other Developmental Activities

12.1.4. Pivotal Clinical Trial

12.1.5. Ongoing Pipeline Activity

13. Emerging Therapies

13.1. Key cross competition- Emerging Therapies

13.2. GSK3228836 (IONIS-HBVRx): GlaxoSmithKline/Ionis Pharma

13.2.1. Product Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Developmental Activities

13.3. JNJ-56136379 (JNJ-6379): Janssen Sciences Ireland

13.3.1. Product Description

13.3.2. Clinical Developmental Activities

13.3.3. Safety and Efficacy

13.4. ABI-H0731: Assembly Biosciences

13.4.1. Product Description

13.4.2. Other Developmental Activities

13.4.3. Clinical Developmental Activities

13.4.4. Safety and Efficacy

13.5. JNJ-73763989 (JNJ-3989) and JNJ-56136379 (JNJ-6379): Janssen and Arrowhead Pharmaceuticals

13.5.1. Product Description

13.5.2. Other Developmental Activities

13.5.3. Clinical Developmental Activities

13.5.4. Safety and Efficacy

13.6. GS-9688 (Selgantolimod): Gilead Sciences

13.6.1. Product Description

13.6.2. Other Developmental Activities

13.6.3. Clinical Developmental Activities

13.6.4. Safety and Efficacy

13.7. RG7854 and RG7907 Combination: Roche

13.7.1. Product Description

13.7.2. Clinical Developmental Activities

13.7.3. Safety and Efficacy

13.8. VIR-2218 and VIR-3434: Vir Biotechnology

13.8.1. Product Description

13.8.2. Clinical Developmental Activities

13.8.3. Safety and Efficacy

14. Conjoint Analysis of CHB

15. Chronic Hepatitis B : 7 Major Market Analysis

15.1. Key Findings

16. Market Outlook

16.1. Market Size of Chronic Hepatitis B

16.1.1. Total Market Size of Chronic Hepatitis B

16.1.2. Market Size of Chronic Hepatitis B by Therapies

17. Market Access and Reimbursement

17.1. Key HTA decisions for CHB

17.2. Patient Access Programs

18. KOL Views

19. Market Drivers

20. Market Barriers

21. SWOT Analysis

22. Unmet Needs

23. Appendix

23.1. Bibliography

23.2. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List of Table

Table 1: Summary of Chronic Hepatitis B, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Anti-hepatitis B virus (HBV) cytokine and nucleot(s)ide analog therapeutic agents

Table 3: Recommendation of EASL

Table 4: Preferred Antiviral Treatment of the HBsAg (+) Patient

Table 5: For Chronic Hepatitis B

Table 6:  Prevalent Population Cases of Chronic Hepatitis B (2019–2032)

Table 7: Diagnosed Prevalent Cases of Chronic Hepatitis B (2019–2032)

Table 8: Gender-specific Cases of Chronic Hepatitis B (2019–2032)

Table 9: Age-specific Cases of Chronic Hepatitis B (2019–2032)

Table 10:  Type-specific Cases of Chronic Hepatitis B (2019–2032)

Table 11: Total Treated Cases of Chronic Hepatitis B (2019–2032)

Table 12: Trials Conducted with Vemlidy in Adults with Chronic HBV Infection

Table 13: Trial Results

Table 14: Tenofovir Alafenamide (TAF), Clinical Trial Description, 2022

Table 15: Comparison of emerging drugs under development

Table 16: IONIS-HBVRx (GSK3228836), Clinical Trial Description, 2022

Table 17: JNJ-56136379 (JNJ-6379); Clinical Trial Description, 2022

Table 18:  ABI- H0731, Clinical Trial Description, 2022

Table 19: JNJ-3989, Clinical Trial Description, 2022

Table 20: Selgantolimod (GS-9688), Clinical Trial Description, 2022

Table 21: RG7854 and RG7907, Clinical Trial Description, 2022

Table 22: VIR-2218 and VIR-3434, Clinical Trial Description, 2022

Table 23: 7MM Market Size of Chronic Hepatitis B in USD Million (2019–2032)

Table 24: 7MM Market Size of CHB by Therapies in USD Million (2019–2032)

Table 25: Key HTA Decisionsfor CHB

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Progression of Hepatitis B infection

Figure 3: Acute Hepatitis B Infection

Figure 4: Chronic Hepatitis B Infection

Figure 5: Signs and Symptoms of Hepatitis B Infection

Figure 6: Signs and Symptoms of Acute and Chronic Hepatitis B Infection

Figure 7: Risk factors of Hepatitis B Infection

Figure 8: Transmission of Hepatitis B Virus

Figure 9: Steps in HBV replication

Figure 10: Pathophysiology of Hepatitis B Infection

Figure 11: Serologic course of hepatitis B virus (HBV) infection.

Figure 12: Complications of Hepatitis B Infection

Figure 13: HBV Screening Algorithm for at-risk patients

Figure 14: Hepatitis B Infection Profile

Figure 15: Transient Elastography using FibroScan

Figure 16: Classes of drugs for the treatment of HBV infection

Figure 17: Types of Interferons

Figure 18: Types of NRTIs

Figure 19: Treatment Pattern

Figure 20: Treatment Pattern  

Figure 21: Week 12 and 24, stopping rules for HBeAg-positive and -negative patients treated with PegIFNa. These rules are based upon viral genotype, HBsAg, and HBV levels.

Figure 22: Treatment algorithm in the case of HBsAg positive and HBeAg negative 

Figure 23: Treatment algorithm in the case of HBsAg (+) and HBeAg (+)

Figure 24: Treatment algorithm in the case of HBeAg Negative

Figure 25: Prevalent Population of Chronic Hepatitis B in the 7MM (2019–2032)

Figure 26: Diagnosed Prevalent Cases of Chronic Hepatitis B in the 7MM (2019–2032)

Figure 27: Gender-specific Cases of Chronic Hepatitis B In the 7MM (2019–2032)

Figure 28: Age-specific Cases of Chronic Hepatitis B in the 7MM (2019–2032)

Figure 29: Type-specific Cases of Chronic Hepatitis B in the 7MM (2019–2032)

Figure 30: Total Treated Cases of Chronic Hepatitis B in the 7MM (2019–2032)

Figure 31: Market Size of Chronic Hepatitis B in the 7MM in USD Million (2019–2032)

Figure 32: 7MM Market Sizeof Chronic Hepatitis B (CHB) by Therapies in USD Million (2019–2032)

Gilead Sciences
GlaxoSmithKline
Ionis Pharma
Janssen Sciences Ireland
Assembly Biosciences
Janssen and Arrowhead Pharmaceuticals
Roche
Vir Biotechnology

 

 

Forward to Friend

Need A Quote